Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5474457 | 0.88 | UGT2B17 (0.46) | UGT2B17KDM4CNR3C1 | |
| SCHEMBL5174356 | 0.74 | UGT2B17 (0.53) | UGT2B17KDM4C | |
| SCHEMBL5471655 | 0.74 | NR3C1 (0.49) | KDM4CNR3C1 | |
| SCHEMBL5477212 | 0.73 | NR3C1 (0.46) | NR3C1 | |
| SCHEMBL5474630 | 0.73 | UGT2B17 (0.51) | UGT2B17KDM4CCYP11B1CYP11B2 | |
| SCHEMBL5471229 | 0.73 | NR3C1 (0.35) | UGT2B17KDM4CNR3C1 | |
| SCHEMBL15286569 | 0.72 | UGT2B17 (0.62) | UGT2B17KDM4C | |
| SCHEMBL5173373 | 0.71 | KDM4C (0.43) | KDM4C | |
| SCHEMBL5173559 | 0.71 | UGT2B17 (0.60) | UGT2B17KDM4CCYP11B1CYP11B2 | |
| SCHEMBL7951928 | 0.70 | MTNR1A (0.57) | UGT2B17KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | UGT2B17 500/4885KDM4C 3261/4885NR3C1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.